VBI Vaccines — Investor Presentation (December 2022)
37 slides from VBI Vaccines's investor presentation, Dec 27, 2022
Slide 1: Corporate Overview December 2022
W/ \S UMpui\\“ Z S j BI TNO VACCINES ACTIVATING THE POWER WITHIN Corporate Overview December 2022
Slide 2: Forward-Looking & Safe Harbor Statements
Forward-Looking & Safe Harbor Statements Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-look
Slide 3: About VBI: Immune to Limitations
About VBI : Immune to Limitations We are a biotechnology company driven by immunology in the pursuit of powerful prevention and treatment of disease Through our innovative approach to virus-like particles, our vision is to stimulate and amplify the human immune system to target and overcome signific
Slide 4: The Science of Virus-Like Particles (VLPs)
The Science of Virus-Like Particles (VLPs) Transforming natural immunity into potent protection and treatment VIPs _—) —— Virus-Like Particles —— Enveloped Virus-Like Particles Antigenic Protein Lipid Bilayer - VBI's Proprietary Platform Technology - Sub-unit vaccines with no infectious material. _-
Slide 5: VBI's Portfolio: Both Sides of the Fight
VBI's Portfolio : Both Sides of the Fight VBI's broad portfolio is designed to power the immune system to prevent and treat disease Disease Technology Phase 1 Phase 2 Approved Prophylactic Vaccine cule VPreHevbrig™ ce ES A Prophylactic Candidates Cytomegalovirus (CMV) —_VBI-1501 evr (i I, COVID-19 (
Slide 6: Notable Recent Accomplishments Prepare VBI for a Transformative 2023
Notable Recent Accomplishments Prepare VBI for a Transformative 2023 i] First US. & EU. Approval Advancement & Expansion of Pipeline fod Strong Financial li, on Position < a MM \ © Zs + PreHevbrio™ (Hepatitis B Vaccine [Recombinant]) approved by the FDA in Nov. 2021, added to the ACIP list of recomm
Slide 7: PreHevbrio
PreHevbrio Hepatitis B Vaccine (Recombinant)
Slide 8: PreHevbrio is the Only 3-Antigen HBV Vaccine
PreHevbrio is the Only 3-Antigen HBV Vaccine PreHevbrio is scientifically differentiated from other HBV vaccines — expressing the three ie B surface antigens (S, pre-Sl, and pre-S2), and manufactured in mammalian cells (vs. yeast PreHevbrio: z& Pre-Sl Antigen @=o The pre-S1 and pre-S2 regions of the
Slide 9: More Adults Achieved Seroprotection with PreHevbrio in Phase 3 Studies
More Adults Achieved Seroprotection with PreHevbrio in Phase 3 Studies PROTECT Phase 3 Study CONSTANT Phase 3 Study 2-arm safety and immunogenicity study 4-arm lot-to-lot consistency study N=1,607 adults aged 18-90 years N=2,838 adults aged 18-45 years Seroprotection Rate! (SPR) 4 Weeks After Receiv
Slide 10: Hepatitis B Remains a Persistent Public Health Problem
Hepatitis B Remains a Persistent Public Health Problem HBV infection is the most common blood-borne infection, with an estimated 240M- 350M chronically-infected individuals worldwide U.S. & Europe : HBV Disease Burden and Challenges oS 0 080 Suboptimal surveillance results Acute HBV disease rates Lo
Slide 11: Public Health Bodies are Changing Tactics
Public Health Bodies are Changing Tactics, Bringing Renewed Prioritization in the Fight to Eliminate HBV Changing U.S. Adult HBV Vaccination Guidelines + In November 2021, the CDC's Advisory Committee on Immunization Practices (ACIP) unanimously voted to move from a risk-based HBV adult vaccination
Slide 12: Commercialization & Upcoming Milestones
Commercialization & Upcoming Milestones Commercialization Partnerships : Cc + VBI entered into a full end-to-end commercialization partnership with Syneos Health in 2019 to support the U.S. Syneos launch of PreHevbrio™, including VBI-dedicated leadership, medical, market access, and sales teams Heal
Slide 13: Hepatitis B (HBV) Therapeutic Candidate: VBI-2601
(@ Hepatitis B (HBV) Therapeutic Candidate : VBI-2601 3
Slide 14: Current Chronic Hepatitis B Landscape
Current Chronic Hepatitis B Landscape Chronic HBV infection represents a critical unmet public health need and an opportunity for meaningful innovation to achieve a functional cure = ji * Over 290 million adults estimated to be infected with CHBV worldwide + Nearly 1million annual deaths from HBV-re
Slide 15: VBI-2601: Potential Critical Component of a Functional Cure
VBI-2601 : Potential to be a Critical Component of a Functional Cure for Chronic HBV Infection Scientific consensus is that a functional cure for HBV is within reach, but will likely require the use of an immunotherapeutic as part of a combination approach A functional cure will likely require the a
Slide 16: VBI-2601 Development Plan & Status
VBI-2601 Development Plan & Status Studies designed & executed in partnership with Brii Biosciences Phase 1b/2a Study Completed in 2021 * Two-part, multi-center, controlled, dose-escalation study (n=44) + Assessed VBI-2601 safety, tolerability, and immunologic antiviral activity in non-cirrhotic pat
Slide 17: Phase 1b/2a Data Demonstrated Significant Restoration of Antibody and T Cell Responses
Phase 1b/2a Data Demonstrated Significant Restoration of Antibody and T Cell Responses Complete dataset announced at the International Liver Congress 2021 Potent re-stimulation of T cell responses to HBV surface antigens (S, Pre-SI, Pre-S2) seen in 67% (Cohort B n=6/9) and 78% (Cohort C n=7/9) of ev
Slide 18: VBI-2601 Ongoing Partnership & Upcoming Milestones
VBI-2601 Ongoing Partnership & Upcoming Milestones Brii Partnership: + In December 2018, VBI announced a license and collaboration agreement with Brii Biosciences (Brii Bio) to develop a functional cure for Hepatitis B + Upfront: $1IM - $4M upfront payment + $7M equity investment Bri Biosciences + M
Slide 19: Coronaviruses
30 Coronaviruses 9
Slide 20: The Virus that Causes COVID-19 Continues to Evolve
The Virus that Causes COVID-19 Continues to Evolve, Leading to Increasing Number of Mutations and Variants of Concerns COVID-19 Variants of Concern Several variants of concern have been identified2, including: a= > B.11.7 — “Alpha” e First detected in UK P>---> @ 81351 - ‘Beta’ First detected in Sou
Slide 21: VBI is Committed to Long-Term Protection Against Coronaviruses
VBI is Committed to the Long-Term Protection Against Coronaviruses VBI's coronavirus pipeline program (VBI-2900) is designed with the goal of eliciting broad and durable immune responses against COVID-19 and coronaviruses VBI-2901 Trivalent Pan-Coronavirus VBI-2902 Monovalent COVID-19 VBI-2905 Monov
Slide 22: VBI-2902 Induced Neutralizing Titers Comparable to Approved mRNA Vaccines
In Phase la Clinical Study, VBI-2902 Induced Neutralizing Titers Comparable to Approved mRNA Vaccines After two doses of 5ug, VBI-2902a elicited neutralizing antibody (nAb) responses 4.3X higher than a panel of convalescent sera, without the use of a next-generation adjuvant Neutralizing Activity! C
Slide 23: New Preclinical Data Demonstrate Immunogenicity of VBI-2905
New Preclinical Data Demonstrate Immunogenicity of VBI-2905 as Both a 2-Dose Regimen and 1-Dose Booster Mice primed with VBI-2902, targeting ancestral SARS-CoV-2, followed by Beta-targeting VBI- 2905 (heterologous boost) resulted in robust and balanced immunity across variants Neutralizing Antibody
Slide 24: Hamster Challenge Data Demonstrate Ability of VBI-2905 to Protect
Hamster Challenge Data Demonstrate Ability of VBI-2905 to Protect Against Infection from Beta Variant of COVID-19 As observed in previous hamster challenge studies of VBI-2902a, neutralizing antibody titers against the Beta variant correlated with protection of disease (weight loss) after challenge
Slide 25: Trivalent VBI-2901 Induced Robust Antibody and Neutralizing Titers
Trivalent VBI-2901 Induced Robust Antibody and Neutralizing Titers Against an Extended Panel of Variants VBI-2901 induced higher and more consistent immunogenicity against Beta, Delta, Kappa, and Lambda variants, with evidence for broadening immunity rather than just boosting cross-reactive antibodi
Slide 26: VBI-2900 Program Summary & Next Steps
VBI-2900 Program Summary & Next Steps v i i eVLP Benefits Strong immune responses when compared to standard recombinants v Multivalency allows for broadly reactive vaccines v Highly potent immunogenicity, comparable to licensed vaccines Proof-of-Concept Data Y towclinical doses (5ug) & no requiremen
Slide 27: Glioblastoma (GBM)
&> } Glioblastoma (GBM)
Slide 28: Unique Approach to Immuno-Oncology
Unique Approach to Immuno-Oncology CMV as a Foreign Viral Antigen + 90% of some solid tumors, including glioblastoma (GBM, breast cancers2, and medulloblastomas? are CMV+ tumors + CMV is not causative, but can influence disease progression of CMV+ tumors * Because CMV is so broadly (and differential
Slide 29: Ongoing Phase 1/2a Study Design & Objectives
Ongoing Phase 1/2a Study Design & Objectives Two-part, open-label, dose escalation study designed to assess the safety, tolerability, and optimal therapeutic dose level of VBI-1901 in recurrent GBM patients Phase 1 (Part A) : Dose-Escalation Phase — Recurrent GBM (any # of recurrences) Study Arm 1:
Slide 30: Tumor Responses Seen in High-Dose Cohorts
Tumor Responses Seen in High-Dose Cohorts VBI-1901 10g + GM-CSF! VBI-1901 10g + ASOT! (High Dose Part A + Part B) (High Dose Part B) Data collected as of November |, 2022 Data collected as of May 9, 2022 = Change in Tumor Size Over Time Change in Tumor Size Over Time = | 1200- => 2 n=I6 = £ A n=10 %
Slide 31: Clinical Responses Seen in High-Dose Cohorts
Clinical Responses Seen in High-Dose Cohorts Based upon Phase 1/2a study data, U.S. FDA granted Fast Track Designation in June 2021 for VBI-1901 + GM- CSF for the treatment of recurrent GBM patients with first tumor recurrence 42 month OS 78 month OS VBI-1901 10g + GM-CSF! As of November |, 2022 I P
Slide 32: VBI-1901 Unmet Need & Upcoming Milestones
VBI-1901 Unmet Need & Upcoming Milestones GBM Represents a Significant Unmet Medical Need: GBM is the most common primary brain cancer with approximately 14,000 annual diagnoses in the U.S, and a low median overall survival of 15-18 months after initial diagnosis! There is no standard of care in the
Slide 33: 33
33
Slide 34: VBI Team
VBI Team —WManagement | @. « = Jeff Baxter David E. Anderson, President & CEO Ph.D. Chief Scientific Officer — Board of Directors Francisco Diaz-Mitoma, MD, Ph.D. Chief Medical Officer Christopher McNulty Chief Financial Officer & Head of Business Development Nell Beattie John Dillman Avi Mazaltov C
Slide 35: VBI Vaccines Global Footprint
VBI Vaccines Global Footprint Ottawa, Canada Research Operations R&D headquarters and facility Cambridge, MA, USA e——— Corporate Headquarters Central location in biotechnology hub Wiel \’ oe. Israel Manufacturing Facility GMP manufacturing facility for the production of the HBV program candidates 35
Slide 36: Summary of Anticipated Upcoming Milestones
Summary of Anticipated Upcoming Milestones Px HBV PreHevbrio (U.S.) Tx HBV VBI-2601 Coronaviruses vBI-2901 GBM vel-1901 7 < wa MM \ Zs Early 2023 : Following European Commission and UK Medicines and Healthcare products Regulatory Agency (MHRA) approvals, VBI expects to make PreHevbri available in ce
Slide 37: VBI Vaccines Inc. www.vbivaccines.com
SS ZB =VBl= = S VBI Vaccines Inc. | www.vbivaccines.com